H.C. Wainwright assumed coverage of Syndax (SNDX) with a Buy rating and $40 price target The firm has conviction that Revuforj will expand its footprint across the relapsed/refractory setting. Revuforj is emerging as the foundational menin inhibitor in acute myeloid leukemia, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Strategic Positioning and Competitive Edge: Syndax Pharmaceuticals’ Buy Rating Reinforced by Revuforj’s Milestones in Leukemia Treatment
- Syndax announces updated NCCN Guidelines for AML
- Synopsys downgraded, Oracle upgraded: Wall Street’s top analyst calls
- 3 Best Stocks to Buy Now, 9/10/2025, According to Top Analysts
- Syndax resumed with a Buy at Stifel